10:49 AM EDT, 08/27/2024 (MT Newswires) -- Johnson & Johnson's ( JNJ ) Janssen-Cilag International unit said Tuesday that the European Commission has expanded approval for Rybrevant, or amivantamab, in combination with chemotherapy to treat adult patients with advanced non-small cell lung cancer with certain genetic deletions or mutations after failure of prior therapy.

The type two extension covers patients with epidermal growth factor receptor Exon 19 deletions or Exon 21 L858R substitution mutations, the company said.

Janssen-Cilag said that the expanded approval is based on results from the phase 3 Mariposa-2 study, in which amivantamab in combination with chemotherapy reduced the risk of disease progression or death by 52% compared with chemotherapy alone.

Price: 162.80, Change: -0.58, Percent Change: -0.35